Skip to main content
Premium Trial:

Request an Annual Quote

Burning Rock, Impact Therapeutics Ink Testing Deal for ATR Inhibitor

NEW YORK – Burning Rock Biotech said Thursday that it has entered a collaboration with Impact Therapeutics under which it is providing testing services to support the pharma firm's development of the ATR inhibitor IMP9064 in both China and the US.

The effort falls under an existing global strategic partnership between the two companies for companion diagnostic development in the context of Impact's pipeline of synthetic lethality cancer drugs, which was announced in August.

The pharma firm has also inked similar deals with other genomic testing companies in China, including Genetron Health.

IMP9064 received Investigational New Drug clearance from the US Food and Drug Administration for a Phase I/II clinical study exploring the compound's use in combination with Impact's PARP inhibitor senaparib.

Under the newly announced collaboration, Burning Rock will perform genetic testing of trial participants in both its Guangzhou, China, and California labs.

Financial terms of the agreement were not disclosed.